Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL.

Clin Cancer Res. 2014 Sep 1;20(17):4488-98. doi: 10.1158/1078-0432.CCR-13-1836. Epub 2014 Mar 31.

2.

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC.

J Clin Oncol. 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7.

3.

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.

J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. Erratum in: J Clin Oncol. 2011 Dec 10;29(35):4725.

PMID:
21969500
4.

Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.

Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.

Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18.

5.

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T.

J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12.

PMID:
27937096
6.

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS.

Mol Cancer Ther. 2013 Jun;12(6):1122-30. doi: 10.1158/1535-7163.MCT-13-0015. Epub 2013 Mar 27.

7.

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE.

J Thorac Oncol. 2014 Sep;9(9):1411-7. doi: 10.1097/JTO.0000000000000274.

8.

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.

9.

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.

PMID:
20100958
10.

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).

Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group.

Lung Cancer. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16.

PMID:
25249428
11.

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.

Mok T, Ladrera G, Srimuninnimit V, Sriuranpong V, Yu CJ, Thongprasert S, Sandoval-Tan J, Lee JS, Fuerte F, Shames DS, Klughammer B, Truman M, Perez-Moreno P, Wu YL.

Lung Cancer. 2016 Aug;98:1-8. doi: 10.1016/j.lungcan.2016.04.023. Epub 2016 May 3.

12.

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, Ahn MJ, Hirashima T, Maemondo M, Kim SW, Kurosaki M, Akinaga S, Park K, Tsai CM, Tamura T, Mitsudomi T, Nakagawa K.

Ann Oncol. 2015 Oct;26(10):2066-72. doi: 10.1093/annonc/mdv288. Epub 2015 Jul 7.

PMID:
26153496
13.

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR.

J Clin Oncol. 2008 Jul 10;26(20):3351-7. doi: 10.1200/JCO.2007.14.0111.

14.

Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.

Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA Jr.

Clin Cancer Res. 2008 Oct 1;14(19):6317-23. doi: 10.1158/1078-0432.CCR-08-0539.

15.

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.

Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ.

Ann Oncol. 2014 Oct;25(10):1941-8. doi: 10.1093/annonc/mdu269. Epub 2014 Jul 23.

16.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
17.

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR.

J Clin Oncol. 2010 Nov 1;28(31):4747-54. doi: 10.1200/JCO.2009.27.9356. Epub 2010 Oct 4.

18.

High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC, Song K, Kim J, Shim YM, Han J.

Histol Histopathol. 2012 Feb;27(2):197-207. doi: 10.14670/HH-27.197.

PMID:
22207554
19.

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.

Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA.

EBioMedicine. 2015 Feb 12;2(3):264-71. doi: 10.1016/j.ebiom.2015.02.005. eCollection 2015 Mar.

20.

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.

Mazières J, Brugger W, Cappuzzo F, Middel P, Frosch A, Bara I, Klingelschmitt G, Klughammer B.

Lung Cancer. 2013 Nov;82(2):231-7. doi: 10.1016/j.lungcan.2013.07.016. Epub 2013 Aug 7.

Supplemental Content

Support Center